M
Maurizio Scaltriti
Researcher at Memorial Sloan Kettering Cancer Center
Publications - 199
Citations - 18413
Maurizio Scaltriti is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Cancer & Breast cancer. The author has an hindex of 55, co-authored 185 publications receiving 14431 citations. Previous affiliations of Maurizio Scaltriti include Autonomous University of Barcelona & Hebron University.
Papers
More filters
Journal ArticleDOI
AKT Inhibition Relieves Feedback Suppression of Receptor Tyrosine Kinase Expression and Activity
Sarat Chandarlapaty,Ayana Sawai,Maurizio Scaltriti,Vanessa Rodrik-Outmezguine,Olivera Grbovic-Huezo,Violeta Serra,Pradip K. Majumder,José Baselga,Neal Rosen +8 more
TL;DR: It is shown that AKT inhibition induces the expression and phosphorylation of multiple receptor tyrosine kinases (RTKs), and combined inhibition of AKT and HER kinase activity is more effective than either alone alone.
Journal ArticleDOI
NTRK fusion-positive cancers and TRK inhibitor therapy
TL;DR: TRK fusion proteins are pathognomonic in certain rare tumour types and present in a small subset of diverse cancer types, including some common cancers; TRK inhibitors have promising efficacy in the treatment of these cancers, in a histology-agnostic manner.
Journal ArticleDOI
Expression of p95HER2, a Truncated Form of the HER2 Receptor, and Response to Anti-HER2 Therapies in Breast Cancer
Maurizio Scaltriti,Federico Rojo,Alberto Ocaña,Judit Anido,Marta Guzman,Javier Cortes,Serena Di Cosimo,Xavier Matias-Guiu,Santiago Ramón y Cajal,Joaquín Arribas,José Baselga +10 more
TL;DR: Breast tumors that express p95HER2 are resistant to trastuzumab and may require alternative or additional anti-HER2-targeting strategies, and women with HER2-overexpressing breast cancers that express this receptor should be responsive to these agents.
Journal ArticleDOI
The Epidermal Growth Factor Receptor Pathway: A Model for Targeted Therapy
Maurizio Scaltriti,José Baselga +1 more
TL;DR: Recent advances in understanding in the mechanisms of receptor activation and function, discovery of primary and secondary EGFR somatic mutations, as well as a new generation of anti-EGFR agents provide new leads on the clinical targeting of this receptor.
Journal ArticleDOI
NVP-BEZ235, a Dual PI3K/mTOR Inhibitor, Prevents PI3K Signaling and Inhibits the Growth of Cancer Cells with Activating PI3K Mutations
Violeta Serra,Benjamin Markman,Maurizio Scaltriti,Pieter Johan Adam Eichhorn,Vanesa Valero,Marta Guzman,Maria Luisa Botero,Elisabeth Llonch,Francesco Atzori,Serena Di Cosimo,Michel Maira,Carlos Garcia-Echeverria,Josep Lluis Parra,Joaquín Arribas,José Baselga +14 more
TL;DR: NVP-BEZ235 inhibits the PI3K/mTOR axis and results in antiproliferative and antitumoral activity in cancer cells with both wild-type and mutated p110-alpha, suggesting that skin may serve as surrogate tissue for pharmacodynamic studies.